Methotrexate Accord Healthcare

Methotrexate, the active ingredient in Methotrexate Accord Healthcare, is a Antimetabolite presented as a parenteral solution for Intraarterial, Intramuscular, Intrathecal use. It treats rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non-Hodgkin lymphoma and gestational trophoblastic disease in appropriate patients.

GNH USA supplies Methotrexate Accord Healthcare as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Methotrexate is employed across several disease families, primarily autoimmune disorders and certain malignancies.

- Rheumatoid arthritis: reduces inflammation and joint damage in patients with active disease. - Psoriasis: slows skin cell proliferation, improving plaque severity. - Acute lymphoblastic leukemia: interferes with malignant cell replication, supporting remission. - Non-Hodgkin lymphoma: inhibits tumor growth as part of combination chemotherapy. - Gestational trophoblastic disease: induces remission by targeting rapidly dividing trophoblastic tissue.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting. - Fatigue or weakness. - Oral mucosal ulceration (mouth sores). - Elevated liver enzymes. - Decreased white blood cell count. - Mild rash or itching.

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Profound bone marrow suppression leading to pancytopenia. - Life‑threatening infections. - Acute renal failure. - Anaphylactic or severe hypersensitivity reactions.

Methotrexate requires careful monitoring and specific safety measures before and during therapy.

- Pregnancy: contraindicated (Category X); avoid use in pregnant women. - Renal function: assess baseline and monitor; adjust dose or discontinue if impaired. - Liver function: perform regular liver enzyme tests; avoid in severe hepatic disease. - Infection risk: monitor for signs of infection; postpone treatment during active infections. - Hematologic monitoring: conduct frequent CBCs; discontinue if severe cytopenia occurs. - Store at room temperature: keep in original container, protect from moisture and light.

Methotrexate interacts with several drug classes, necessitating vigilance to prevent toxicity.

Major Interactions (Avoid): - Nonsteroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Aminoglycoside antibiotics: potentiate nephrotoxic effects. - Live vaccines: heightened risk of severe infection. - High‑dose folic acid supplements: may diminish therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: may raise hematologic toxicity. - Penicillins (e.g., ampicillin): can elevate methotrexate plasma levels. - Proton pump inhibitors: may affect renal clearance of methotrexate. - Trimethoprim: increased risk of myelosuppression.